. 2025 Jul 24;86:103369. doi: 10.1016/j.eclinm.2025.103369

Table 3.

Pooled results of individual TRAEs for vaccine therapy after first-line therapy.

TRAEs	Study and sample	Pooled analysis		Heterogeneity
TRAEs	Study and sample	OR (95% CI)	P value	I² (%)	P value
Cough	2208¹⁵^,¹⁸^,¹⁹	1.18 (0.96–1.46)	0.132	5.7	0.346
Dyspnoea	2054¹⁵^,¹⁸^,²³	1.03 (0.82–1.28)	0.810	0	0.819
Fatigue	2623¹⁶^,¹⁸^,¹⁹^,²³	0.97 (0.65–1.46)	0.880	57.2	0.072
Asthenia	845¹⁵^,¹⁶^,²³^,²⁵	0.87 (0.38–1.99)	0.739	75.2	0.007
Body or extremity pain	2245¹⁶^,¹⁸^,¹⁹	1.40 (0.87–2.27)	0.169	61.4	0.075
Musculoskeletal pain	1297¹⁵^,¹⁶^,¹⁹^,²³	1.10 (0.77–1.59)	0.596	5.9	0.346
Headache	2666¹⁵^,¹⁸^,¹⁹^,²³^,²⁵	1.75 (1.02–3.00)	0.041	69.6	0.010
Nausea	2703¹⁶^,¹⁸^,¹⁹^,²³^,²⁵	1.37 (0.87–2.16)	0.178	56.8	0.055
Decreased appetite or anorexia	2848¹⁵^,¹⁶^,¹⁸^,¹⁹^,²³^,²⁴	1.00 (0.63–1.60)	0.998	54.9	0.050
Vomiting	670¹⁶^,²³^,²⁵	2.66 (0.41–17.41)	0.308	83.6	0.002
Arthralgia	2878¹⁵^,¹⁶^,¹⁸^,¹⁹^,²³^,²⁵	1.14 (0.68–1.91)	0.628	56.1	0.044
Injection site reaction	1598¹⁵^,¹⁶^,¹⁹^,²¹^,23, 24, 25	14.97 (3.18–70.40)	0.001	90.1	<0.001
Fever	1377¹⁵^,¹⁶^,¹⁹^,²³^,²⁵	2.47 (0.99–6.18)	0.054	80.2	<0.001
Skin symptoms	1377¹⁵^,¹⁶^,¹⁹^,²³^,²⁵	1.35 (0.27–6.66)	0.714	88.3	<0.001